Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BX67

UPID:
JAM3_HUMAN

ALTERNATIVE NAMES:
JAM-2; Junctional adhesion molecule 3

ALTERNATIVE UPACC:
Q9BX67; B3KWG9; Q8WWL8; Q96FL1

BACKGROUND:
Junctional adhesion molecule C, known alternatively as JAM-2 or Junctional adhesion molecule 3, is integral to cell-cell adhesion, hematopoietic stem cell dynamics, and leukocyte migration. It facilitates the assembly of cell polarity complexes during spermatid differentiation and plays a significant role in angiogenesis and the regulation of cell migration. Its function as a counter-receptor for ITGAM also underscores its importance in leukocyte-platelet interactions and polymorphonuclear neutrophils' transepithelial migration.

THERAPEUTIC SIGNIFICANCE:
Given its critical functions and involvement in a syndrome characterized by congenital cataracts and severe brain abnormalities, Junctional adhesion molecule C represents a promising target for drug discovery. Exploring the therapeutic potential of modulating JAM-C's activity could lead to breakthrough treatments for diseases marked by impaired cell-cell interactions and migration, including strategies to address the devastating outcomes of the associated brain syndrome.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.